English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

JNCI | Editorials 569 Some medical decisions are fairly straightforward. If you break a leg, the recommended treatment is a cast, elevation, and crutches. But if your breast biopsy leads to a diagnosis of ductal carcinoma in situ (DCIS), the treatment path is much less clear. A diagnosis of DCIS brings uncertainty. With the introduction of population-wide screening mammography, radiologists have increasingly recommended evaluation of subtle breast abnormalities. Concurrently, the incidence of DCIS has dramatically Ductal Carcinoma In Situ (DCIS): Raising Signposts on an Ill-Marked Treatment Path